The FDA's Pharmacy Compounding Advisory Committee voted 8-6 in July 2026 to recommend adding BPC-157 to the 503A Bulk Drug Substances List for pharmacy compounding, overriding staff concerns over limited human safety and efficacy data. This non-binding step followed removal from Category 2 earlier in 2026 but does not authorize use; formal Category 1 placement requires FDA acceptance and notice-and-comment rulemaking, a process that routinely spans eight to twelve months. Trader sentiment reflects uncertainty around whether the agency will complete that rulemaking by key 2026 deadlines amid competing priorities, external support for expanded access, and ongoing questions about clinical evidence. No final agency decision has been announced as of mid-September 2026.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於最新
2026-12-31
2026年12月31日
50%
$4,536 交易量
2026年12月31日
$2,534 交易量
50%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 in July 2026 to recommend adding BPC-157 to the 503A Bulk Drug Substances List for pharmacy compounding, overriding staff concerns over limited human safety and efficacy data. This non-binding step followed removal from Category 2 earlier in 2026 but does not authorize use; formal Category 1 placement requires FDA acceptance and notice-and-comment rulemaking, a process that routinely spans eight to twelve months. Trader sentiment reflects uncertainty around whether the agency will complete that rulemaking by key 2026 deadlines amid competing priorities, external support for expanded access, and ongoing questions about clinical evidence. No final agency decision has been announced as of mid-September 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
市場開放時間： Jun 22, 2026, 10:10 PM ET
交易量
$4,536結束日期
2027-01-01市場開放時間
Jun 22, 2026, 10:10 PM ETThis market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted 8-6 in July 2026 to recommend adding BPC-157 to the 503A Bulk Drug Substances List for pharmacy compounding, overriding staff concerns over limited human safety and efficacy data. This non-binding step followed removal from Category 2 earlier in 2026 but does not authorize use; formal Category 1 placement requires FDA acceptance and notice-and-comment rulemaking, a process that routinely spans eight to twelve months. Trader sentiment reflects uncertainty around whether the agency will complete that rulemaking by key 2026 deadlines amid competing priorities, external support for expanded access, and ongoing questions about clinical evidence. No final agency decision has been announced as of mid-September 2026.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
交易量
$4,536結束日期
2027-01-01市場開放時間
Jun 22, 2026, 10:10 PM ETThe FDA's Pharmacy Compounding Advisory Committee voted 8-6 in July 2026 to recommend adding BPC-157 to the 503A Bulk Drug Substances List for pharmacy compounding, overriding staff concerns over limited human safety and efficacy data. This non-binding step followed removal from Category 2 earlier in 2026 but does not authorize use; formal Category 1 placement requires FDA acceptance and notice-and-comment rulemaking, a process that routinely spans eight to twelve months. Trader sentiment reflects uncertainty around whether the agency will complete that rulemaking by key 2026 deadlines amid competing priorities, external support for expanded access, and ongoing questions about clinical evidence. No final agency decision has been announced as of mid-September 2026.
基於Polymarket數據的AI實驗性摘要。這不是交易建議，也不影響該市場的結算方式。 · 更新於
警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions